Protagonist Therapeutics announced that it has exercised its right to opt‑out of the 50:50 U.S. profit‑and‑loss sharing arrangement with Takeda for the investigational peptide rusfertide. The opt‑out election makes the company eligible for up to $400 million in payments—$200 million upon election and an additional $200 million upon FDA approval of rusfertide for polycythemia vera. In addition, a $75 million milestone payment is triggered at FDA approval, bringing the total potential cash tied to the opt‑out and approval to $475 million.
Under the new royalty‑based structure, Protagonist will receive up to $975 million in milestone payments and tiered royalties ranging from 14 % to 29 % on worldwide net sales. The shift from a 50:50 profit‑sharing model to a structure focused on upfront payments, milestones, and royalties provides the company with a substantial near‑term cash infusion while preserving a potentially larger long‑term upside through royalties. This change also transfers full U.S. commercialization responsibility and risk to Takeda, allowing Protagonist to de‑risk its commercialization strategy for rusfertide.
The decision comes amid strong regulatory momentum for rusfertide. The FDA accepted the New Drug Application in March 2026 with priority review and set a PDUFA goal for the third quarter of 2026. Rusfertide also holds Breakthrough Therapy, Orphan Drug, and Fast Track designations, underscoring its potential to address a rare chronic blood disorder. The opt‑out move therefore positions Protagonist to capture immediate cash while maintaining a meaningful stake in future sales as the drug approaches approval.
Protagonist’s financial context further explains the rationale for the opt‑out. The company reported a net loss of $11.7 million in Q1 2025, a sharp decline from a net income of $207.3 million in Q1 2024, and a net loss of $44.4 million in Q4 2025 versus a net income of $131.7 million in Q4 2024. With $646 million in cash, cash equivalents, and marketable securities as of December 31 2025, the company has a solid runway but has been operating at a loss. The opt‑out provides non‑dilutive cash that can be deployed to fund its broader pipeline and return value to shareholders.
Management emphasized the strategic intent behind the move. CEO Dinesh V. Patel said, "Exercising our opt‑out right reflects our conviction in rusfertide and secures what we believe is the most attractive risk‑adjusted value outcome for Protagonist and its shareholders as the hepcidin mimetic peptide approaches a potential approval." He added, "This election provides meaningful near‑term non‑dilutive cash, materially enhances our long‑term economic participation through milestones and worldwide royalties, and further strengthens our ability to invest in our broader pipeline and return value to shareholders."
The opt‑out transaction therefore strengthens Protagonist’s balance sheet, reduces commercialization risk, and preserves a significant upside through milestone payments and royalties, while Takeda assumes full U.S. commercialization responsibility. The move aligns with the company’s strategy to focus on pipeline development and shareholder value creation as rusfertide moves closer to regulatory approval.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.